A chance for Rituximab in Primary Biliary Cholangitis–Autoimmune Hepatitis Overlap Syndrome.
Revista Andaluza de Patología Digestiva · 11.03.2026 · 49 (1) · 29-31
DOI: 10.37352/2026491.5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Andaluza de Patología Digestiva, online erschienen am 11.03.2026. Verfasst von J Pereira Martinez und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) may coexist as an overlap syndrome, which can be challenging to diagnose and manage. In this case report, we describe a patient with AIH–PBC overlap syndrome refractory to conventional immunosuppressive therapy and with steroid-dependent disease. Rituximab was administered as rescue therapy, achieving biochemical normalization. This case supports the potential role of rituximab as a therapeutic option in patients refractory to standard immunosuppressive treatments.
Zitieren
APA
Martinez, J. P., Sánchez, A. R., Fernández, I. H., & Martín, J. S. (2026). A chance for Rituximab in Primary Biliary Cholangitis–Autoimmune Hepatitis Overlap Syndrome. Revista Andaluza de Patología Digestiva, 49(1), 29-31. https://doi.org/10.37352/2026491.5
Vancouver
Martinez JP, Sánchez AR, Fernández IH, Martín JS. A chance for Rituximab in Primary Biliary Cholangitis–Autoimmune Hepatitis Overlap Syndrome. Revista Andaluza de Patología Digestiva. 2026;49(1):29-31. doi:10.37352/2026491.5
BibTeX
@article{Martinez2026,
author = {Martinez, J Pereira and Sánchez, A Ruiz and Fernández, I Herrería and Martín, JM Sousa},
title = {A chance for Rituximab in Primary Biliary Cholangitis–Autoimmune Hepatitis Overlap Syndrome},
journal = {Revista Andaluza de Patología Digestiva},
year = {2026},
volume = {49},
number = {1},
pages = {29--31},
doi = {10.37352/2026491.5}
}
EUVIMED